Well-tolerated compound holds potential hope for the treatment of Huntington’s disease
A highly detailed 3D rendering of a double helix human DNA in blue color, with small carbon elements and light effects on a dark gray-blue background. The image shows an angle of view of different
In a new study, published recently in Nature Medicine, researchers have presented findings highlighting a compound termed KD3010 as a potentially effective treatment for slowing Huntington’s disease (HD) symptoms and decline. The compound was previously tested for use in the treatment of diabetes in a Phase Ib trial where it was well-tolerated in participants. "We're very excited by our preclinical testing of this compound (KD3010)," commented lead author Albert La Spada (University of California, San Diego, USA). Following previous discovery of the significant role of PGC-1 alpha, a regulatory protein central to the creation and operation of mitochondria, as well...
